Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CES1 | P23141 | 3/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170079 | 0.86 | CYP3A4 (0.50) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| SCHEMBL1566658 | 0.83 | CYP3A4 (0.68) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| SCHEMBL132541 | 0.81 | CYP3A4 (0.65) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| SCHEMBL29944162 | 0.81 | CYP3A4 (0.65) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| SCHEMBL54880 | 0.79 | ALDH1A1 (0.66) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| SCHEMBL3291219 | 0.79 | ALDH1A1 (0.66) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| SCHEMBL10969867 | 0.79 | CYP3A4 (0.63) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| SCHEMBL1498134 | 0.79 | CYP3A4 (0.63) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| Nitromide SCHEMBL193674 | 0.79 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 | |
| Potassium Ion SCHEMBL12393446 | 0.79 | CYP3A4 (0.63) | CYP3A4SMN1; SMN2CES1CES2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | LIPOSCIENCES, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3067359-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Petersen, Scott G. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2014-11-06 | — | — | US | disclosed |
| US-20130210786-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | PHYTOPHARM PLC (GB) | 2013-08-15 | — | — | US | disclosed |
| EP-2595621-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | Phytopharm PLC (GB) | 2013-05-29 | — | — | EP | disclosed |
| EP-2479183-A2 | Polymorphs of sarsasapogenin | Phytopharm PLC (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-20120034193-A1 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS | PHYTOPHARM PLC (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2012010896-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | PHYTOPHARM PLC (GB) | 2012-01-26 | — | — | WO | disclosed |
| EP-2402362-A2 | Crystalline forms of smilagenin | Phytopharm PLC (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-20060041119-A1 | Stereospecific reduction of Sapogen-3-ones | PHYTOPHARM PLC (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2005105825-A2 | CRYSTALLINE AND AMORPHOUS FORMS OF SMILAGENIN | PHYTOPHARM PLC (GB) | 2005-11-10 | — | — | WO | disclosed |
| EP-1558627-A1 | STEREOSPECIFIC REDUCTION OF SAPOGEN-3-ONES | Phytopharm Plc (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050130948-A1 | Therapeutic methods and uses of sapogenins and their derivatives | PHYTOPHARM PLC (GB) | 2005-06-16 | — | — | US | disclosed |
| EP-1490071-A2 | THERAPUTIC METHODS AND USES OF SAPOGENINS AND THEIR DERIVATIVES | Phytopharm Plc (GB) | 2004-12-29 | — | — | EP | disclosed |
| US-20040147495-A1 | Sapogenin derivatives, their synthesis and use, and methods based upon their use | PHYTOPHARM PLC (GB) | 2004-07-29 | — | — | US | disclosed |
| WO-2004037845-A1 | STEREOSPECIFIC REDUCTION OF SAPOGEN-3-ONES | PHYTOPHARM PLC (GB) | 2004-05-06 | — | — | WO | disclosed |
| EP-1383787-A2 | SAPOGENIN DERIVATIVES, THEIR SYNTHESIS AND USE | PHYTOTECH LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003082893-A2 | THERAPUTIC METHODS AND USES OF SAPOGENINS AND THEIR DERIVATIVES | PHYTOPHARM PLC (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002079221-A2 | SAPOGENIN DERIVATIVES, THEIR SYNTHESIS AND USE | PHYTOTECH LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130948-A1 | Therapeutic methods and uses of sapogenins and their derivatives | PMP22, GAP43, NLN | CYP3A4 4642/4885SMN1; SMN2 4/4885CES1 2821/4885 |
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | CYP3A4 4878/4885SMN1; SMN2 567/4885CES1 3899/4885 |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | NCL, PHOSPHO1, POLN | CYP3A4 4881/4885SMN1; SMN2 543/4885CES1 3750/4885 |
| US-20120034193-A1 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS | BDNF, NGF, GFRA1 | CYP3A4 2252/4885SMN1; SMN2 80/4885CES1 1314/4885 |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | CYP3A4 4878/4885SMN1; SMN2 567/4885CES1 3899/4885 |
| US-20060041119-A1 | Stereospecific reduction of Sapogen-3-ones | HSD3B2, HSD3B1, HSD17B7 | CYP3A4 783/4885SMN1; SMN2 1490/4885CES1 878/4885 |
| US-20130210786-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | SNCA, DBH, COMT | CYP3A4 524/4885SMN1; SMN2 1238/4885CES1 676/4885 |
| US-20040147495-A1 | Sapogenin derivatives, their synthesis and use, and methods based upon their use | GAP43, ACHE, CHRNA10 | CYP3A4 2734/4885SMN1; SMN2 23/4885CES1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.